Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection

Qin Lizeng; Pia Skott; Samer Sourial; Charlotta Nilsson; Sören Andersson; Mariethe Ehnlund; Nuno Taveira; Ewa Björling

doi:10.1016/S0042-6822(02)00088-0

Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection

Qin Lizeng, Pia Skott, Samer Sourial, Charlotta Nilsson, Sören Andersson, Mariethe Ehnlund, Nuno Taveira, Ewa Björling

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

In the present study, we sought to define the importance of serum IgA (sIgA)-mediated immunity in HIV-2 infection. Serum samples from a total of 29 HIV-2-infected patients from Guinea-Bissau (n = 20) and Portugal (n = 9) were studied. Samples from seronegative individuals were used as controls. Antibody reactivity to native and recombinant envelope glycoproteins as well as peptides representing various regions of the envelope glycoproteins was investigated. Furthermore, the capacity of purified IgA to neutralize the HIV-2_SBL6669 strain was tested. All serum samples showed IgA reactivity against whole HIV-2 antigen. Twenty-eight out of 29 IgA samples (96%) reacted with native HIV-2 gp125, 26/29 (90%) with recombinant gp105, and 29/29 (100%) with recombinant gp36. When using peptides, the most prominent IgA reactivity was seen against the peptide representing aa 644-658 of the transmembranous protein gp36, to which 72% of the sera reacted. Purified sIgA antibodies showed neutralizing effects against HIV-2_SBL6669 in 17/29 cases (59%). This work decribes the HIV-2-specific sIgA antigenic response. Moreover, our findings show, for the first time, that sIgA may play a role in the in vitro neutralization of HIV-2.

Original language	English
Pages (from-to)	225-232
Number of pages	8
Journal	Virology
Volume	308
Issue number	2
DOIs	https://doi.org/10.1016/S0042-6822(02)00088-0
Publication status	Published - 10 Apr 2003
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0042-6822(02)00088-0

Cite this

@article{1e2d00bad376491a8590133bc1c7ee6b,

title = "Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection",

abstract = "In the present study, we sought to define the importance of serum IgA (sIgA)-mediated immunity in HIV-2 infection. Serum samples from a total of 29 HIV-2-infected patients from Guinea-Bissau (n = 20) and Portugal (n = 9) were studied. Samples from seronegative individuals were used as controls. Antibody reactivity to native and recombinant envelope glycoproteins as well as peptides representing various regions of the envelope glycoproteins was investigated. Furthermore, the capacity of purified IgA to neutralize the HIV-2SBL6669 strain was tested. All serum samples showed IgA reactivity against whole HIV-2 antigen. Twenty-eight out of 29 IgA samples (96%) reacted with native HIV-2 gp125, 26/29 (90%) with recombinant gp105, and 29/29 (100%) with recombinant gp36. When using peptides, the most prominent IgA reactivity was seen against the peptide representing aa 644-658 of the transmembranous protein gp36, to which 72% of the sera reacted. Purified sIgA antibodies showed neutralizing effects against HIV-2SBL6669 in 17/29 cases (59%). This work decribes the HIV-2-specific sIgA antigenic response. Moreover, our findings show, for the first time, that sIgA may play a role in the in vitro neutralization of HIV-2.",

author = "Qin Lizeng and Pia Skott and Samer Sourial and Charlotta Nilsson and S{\"o}ren Andersson and Mariethe Ehnlund and Nuno Taveira and Ewa Bj{\"o}rling",

year = "2003",

month = apr,

day = "10",

doi = "10.1016/S0042-6822(02)00088-0",

language = "English",

volume = "308",

pages = "225--232",

journal = "Virology",

issn = "0042-6822",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection

AU - Lizeng, Qin

AU - Skott, Pia

AU - Sourial, Samer

AU - Nilsson, Charlotta

AU - Andersson, Sören

AU - Ehnlund, Mariethe

AU - Taveira, Nuno

AU - Björling, Ewa

PY - 2003/4/10

Y1 - 2003/4/10

N2 - In the present study, we sought to define the importance of serum IgA (sIgA)-mediated immunity in HIV-2 infection. Serum samples from a total of 29 HIV-2-infected patients from Guinea-Bissau (n = 20) and Portugal (n = 9) were studied. Samples from seronegative individuals were used as controls. Antibody reactivity to native and recombinant envelope glycoproteins as well as peptides representing various regions of the envelope glycoproteins was investigated. Furthermore, the capacity of purified IgA to neutralize the HIV-2SBL6669 strain was tested. All serum samples showed IgA reactivity against whole HIV-2 antigen. Twenty-eight out of 29 IgA samples (96%) reacted with native HIV-2 gp125, 26/29 (90%) with recombinant gp105, and 29/29 (100%) with recombinant gp36. When using peptides, the most prominent IgA reactivity was seen against the peptide representing aa 644-658 of the transmembranous protein gp36, to which 72% of the sera reacted. Purified sIgA antibodies showed neutralizing effects against HIV-2SBL6669 in 17/29 cases (59%). This work decribes the HIV-2-specific sIgA antigenic response. Moreover, our findings show, for the first time, that sIgA may play a role in the in vitro neutralization of HIV-2.

AB - In the present study, we sought to define the importance of serum IgA (sIgA)-mediated immunity in HIV-2 infection. Serum samples from a total of 29 HIV-2-infected patients from Guinea-Bissau (n = 20) and Portugal (n = 9) were studied. Samples from seronegative individuals were used as controls. Antibody reactivity to native and recombinant envelope glycoproteins as well as peptides representing various regions of the envelope glycoproteins was investigated. Furthermore, the capacity of purified IgA to neutralize the HIV-2SBL6669 strain was tested. All serum samples showed IgA reactivity against whole HIV-2 antigen. Twenty-eight out of 29 IgA samples (96%) reacted with native HIV-2 gp125, 26/29 (90%) with recombinant gp105, and 29/29 (100%) with recombinant gp36. When using peptides, the most prominent IgA reactivity was seen against the peptide representing aa 644-658 of the transmembranous protein gp36, to which 72% of the sera reacted. Purified sIgA antibodies showed neutralizing effects against HIV-2SBL6669 in 17/29 cases (59%). This work decribes the HIV-2-specific sIgA antigenic response. Moreover, our findings show, for the first time, that sIgA may play a role in the in vitro neutralization of HIV-2.

UR - http://www.scopus.com/inward/record.url?scp=0037431316&partnerID=8YFLogxK

U2 - 10.1016/S0042-6822(02)00088-0

DO - 10.1016/S0042-6822(02)00088-0

M3 - Article

C2 - 12706073

AN - SCOPUS:0037431316

SN - 0042-6822

VL - 308

SP - 225

EP - 232

JO - Virology

JF - Virology

IS - 2

ER -

Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this